2024-04-25  5:36:17 PM Chg. -0.040 Volume Bid2024-04-25 Ask2024-04-25 Market Capitalization Dividend Y. P/E Ratio
1.850EUR -2.12% 6,947
Turnover: 12,672.425
-Bid Size: - -Ask Size: - 23.81 mill.EUR 27.10% 0.80

Business description

NanoRepro AG is an innovative leader in the development, manufacturing and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use, in the domestic and international markets. Since October 2008, NanoRepro has been publicly listed with its headquarters located in Marburg, Germany. Its goal is to provide accuracy in self-diagnostics for rapid disease detection. Self-diagnostics is a fast growing market shaped by the ever-increasing health conscious of the population and healthcare spending. The rapid diagnostic tests offer significant advantages over all available competitive products due to the flexibility in product design, in-depth market understanding and best practices of just-in-time manufacturing. The company has currently around 25 rapid diagnostic tests within the portfolio addressing various healthcare needs (family planning, preventive healthcare, allergies, and infectious diseases).
 

Management board & Supervisory board

CEO
Lisa Jüngst
Management board
Stefan Pieh
Supervisory board
Dr. Olaf Stiller, Michael J. Tillmann, Clemens Jakopitsch, Dr. Bhuwnesh Agrawal, Hauke Heinz Hillmer, Rainer Barth
 

Company data

Name: NanoRepro AG
Address: Untergasse 8,D-35037 Marburg
Phone: +49-6421-951449
Fax: +49-6421-951451
E-mail: info@nano.ag
Internet: www.nano.ag
Industry: -
Sector: -
Sub sector: -
End of financial year: 12-31
Free Float: 88.00%
IPO date: -

Investor relations

Name: Lisa Jüngst
IR phone: -
IR Fax: -
IR e-mail: juengst@nanorepro.com

Main Shareholders

Freefloat
 
88.00%
Management
 
12.00%